Will Pfizer's Paxlovid Go The Lagevrio Way In India?
Comirnaty – A Lost Opportunity
Executive Summary
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
You may also be interested in...
COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
Pfizer's India MD On Funding Healthcare Startups
Pfizer’s India managing director, S Sridhar, talks to Scrip about funding startups focused on oncology and digital health, via the CSR route. Two such startups, SiCureMi and Tinkertech, are close to commercialization. Meanwhile, Pfizer's pact with MPP will allow the COVID-19 antiviral Paxlovid to find its way to India and 94 other low- and middle-income countries
Pfizer Executive On Paxlovid’s Development And Design Journey
Senior Pfizer executive outlines the accelerated development approach for Paxlovid, one that took just 17 months, but was done without cutting any corners for safety and also sought to guard against resistance from the design perspective.